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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy and safety of amphetamines for ADHD in children and adolescents.
B A C K G R O U N D
Description of the condition
Attention deficit hyperactivity disorder (ADHD) is among the
most common pediatric psychiatric conditions, affecting around
5% of children worldwide (Polzancky 2007). ADHD is character-
ized by three core symptoms: inattention, impulsivity, and hyper-
activity, which aremore frequently displayed thanwould be typical
in children of the same age (APA 2000). The core symptoms are
often presented to various degrees in different children, breaking
ADHD down into three subtypes: the predominantly inattentive
type, the predominantly hyperactive-impulsive type, and the com-
bined type (i.e. children displaying both inattention and hyper-
activity) (APA 2000). The condition is often diagnosed through
a rigorous set of criteria at a young age, usually between the ages
of three and six (NIMH 2009). The potential for comorbidities is
extremely high in this population and they are present in almost
two-thirds of pediatric ADHD cases, with the most common be-
ing oppositional defiant disorder (ODD) (50%), conduct disor-
der (CD) (35%), anxiety disorder (33%), and depression (33%)
(AHRQ 1999; Mayes 2009).
The symptoms of ADHD have been shown to permeate a child’s
performance across multiple settings, having long-term effects on
their academic performance and social development. Studies have
also shown that children with ADHD are more likely to be more
irritable, impatient, and aggressive (NIH 2000). In addition, fam-
ilies who have children with ADHD often experience higher lev-
els of parental stress and frustration, marital disruption, and so-
cial isolation (Edwards 1995). It has been estimated that 50% of
childhood ADHD cases will persist into adolescence and adult-
hood (Biederman 1993), making it a chronic lifetime condition
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for many.
Description of the intervention
A wide variety of treatments have been used for the management
of ADHD including psychosocial interventions, dietary manage-
ment, herbal and homeopathic remedies, and biofeedback; how-
ever, for the past few decades, stimulant medication has been the
first line of treatment (APA 2000) and has been found to be effec-
tive in 70% to 90% of school-aged children (Wigal 1999; NIH
2000). Amphetamines are the second most frequently prescribed
psychostimulants for pediatric ADHD, and are becoming an in-
creasingly popular alternative for children who fail to respond to
methylphenidate (Buck 2002). There are currently four differ-
ent amphetamine preparations available. These include racemic
amphetamine sulfate, dexamphetamine (dextroamphetamine or
d-amphetamine sulfate), lisdexamphetamine, and a newer am-
phetamine mixture that contains four different amphetamine salts
(Buck 2002).
How the intervention might work
Evidence has suggested that ADHD may be the result of insuf-
ficient production of norepinephrine and dopamine in the pre-
frontal cortex (Arnsten 2006). As such, the executive functions car-
ried out by the prefrontal cortex are impaired, resulting in forget-
fulness, distractibility, impulsivity, and inappropriate social behav-
iors (Anderson 1999).Others believe that the limbic systemplays a
major role in the pathophysiology of ADHD, and it is thought that
hyperactivity and impulsivity result from abnormally low tonic
dopamine activity within this region of the brain (Moore 2011).
In either case, as a psychostimulant, amphetamines are thought to
disrupt normal reuptake of neurotransmitters thereby increasing
levels of norepinephrine anddopamine in these regions of the brain
and resulting in restored executive functioning (Arnsten 2006).
A Cochrane review of amphetamines for ADHD in adults found
they improved short-term symptom severity (Castells 2011).
Why it is important to do this review
Despite being one of the most thoroughly researched disorders in
medicine, one of the major controversies regarding ADHD is the
use of psychostimulants as a treatment option. While current evi-
dence suggests that amphetaminesmay be beneficial for improving
the core symptoms of ADHD, its effects on academic and social
domains remain inconsistent and unclear (NIH 2000).Wide vari-
ations in the use and prescription of amphetamines across commu-
nities suggests that there is a lack of consensus among practition-
ers regarding which people with ADHD should be treated with
amphetamines. In spite of the wide use of amphetamines as a first
or second line of therapy for pediatric ADHD, a systematic review
assessing their efficacy and safety in this population has never been
conducted. As primary stakeholders, it is imperative for healthcare
providers, parents, and those diagnosed with ADHD to be aware
of the most suitable treatment options available, and how they
differ in terms of their efficacy and safety profiles. Our synthesis
of all available randomized controlled trials on the efficacy and sa-
fety of amphetamines for pediatric ADHD will provide evidence
to better inform clinical practice and further research planning of
ADHD management.
O B J E C T I V E S
To assess the efficacy and safety of amphetamines for ADHD in
children and adolescents.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Parallel and cross-over randomized controlled trials (RCTs).
Types of participants
Children and adolescents (less than 18 years of age) with a clin-
ical diagnosis of ADHD according to specified diagnostic crite-
ria, such as the DSM-III (APA 1987), DSM-IV (APA 2000), or
equivalent. We will include trials that involve participants with
some comorbid conditions (oppositional defiant disorder (ODD),
conduct disorder (CD), anxiety, depression, learning disability).
We will exclude trials that include participants with neuropsycho-
logical comorbidities, which require highly specialized treatment
programs (for example, autism, bipolar disorder, psychosis).
Types of interventions
Intervention: any oral form of amphetamine (i.e. amphetamine,
dexamphetamine, lisdexamphetamine, and mixed amphetamine
salts (Adderall)), at any dose.
Control: placebo.
Types of outcome measures
Primary outcomes
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1. Change in core ADHD symptoms (inattention,
hyperactivity, impulsivity), as measured by a validated scale rated
by children, parents, teachers, clinicians, or assessors such as the
revised Conners’ Parent Rating Scale (CPRS-R) (Conners 1998),
the revised Conners’ Teacher Rating scale (CTRS-R) (Conners
1998a), or the ADHD Rating Scale (Zhang 2005)*
Change scores and endpoint scores will be collected; however,
priority will be given to change scores when both types of scores
are available in the same study.
Secondary outcomes
1. Clinical improvement measured the by Clinical Global
Impression-Improvement (CGI-I) scale*
2. School or academic performance as measured by school test
results or by a validated scale*
3. Parental stress measured by a validated scale (for example,
Parenting Stress Index (PSI) (Abidin 1997))*
4. Quality of life measured by a validated scaled (for example,
Pediatric Quality of Life Inventory-32 (PedsQL-32) (Varni
1998))*
5. Retention: proportion of randomized participants who
completed the trial
Adverse events
1. Proportion of adverse events*
2. Proportion of participants who experienced at least one
adverse event as reported in the trials
3. Proportion of participants that drop out due to any adverse
event
Outcomes marked with an * will be used to populate a ’Summary
of findings’ table.
Search methods for identification of studies
Wewill attempt to identify all relevant published and unpublished
RCTs, irrespective of language, using the terms: Attention Deficit
with Hyperactivity Disorder AND (child OR adolescent OR pae-
diatric) AND (amphetamines OR dexamphetamine OR lisdex-
amphetamine OR mixed amphetamine salts).
Electronic searches
We will search the following electronic databases.
1. Cochrane Central Register of Controlled Trials
(CENTRAL)
2. MEDLINE
3. Medline In-Process & Other Non-Indexed Citations
4. EMBASE
5. PsycINFO
6. ProQuest Dissertations and Theses
7. metaRegister of Controlled Trials (mRCT)
8. The NHS National Research Register Archive
9. ClinicalTrials.gov
10. Networked Digital Library of Theses and Dissertations
(NTLTD)
The complete search strategy for MEDLINE is below and will be
modified as appropriate for the other databases.
1. exp Amphetamines/
2. (amphetamine$ or dexamphetamine$ or
methamphetamine$ or dextroamphetamine$ or
lisdexamphetamine$ or vyvanase$ or Dexedrin3 or desoxyn$ or
adderall$).mp.
3. Central Nervous System Stimulants/
4. 1 or 2 or 3
5. exp Attention Deficit Disorder with Hyperactivity/














20. (minimal adj3 brain$ adj3 (damag$ or disorder$ or
dysfunc$)).tw.
21. (attention$ adj3 (deficit$ or disorder$ or dysfunc$)).tw.
22. (behav$ adj3 (dysfunc$ or disorder$)).tw.
23. (behav$ adj3 (dysfunc$ or disorder$)).tw.





29. (adoles$ or teen$ or youth$ or young people or young
person$).tw.
30. (child$ or toddler$ or preschool$ or pre-school or




34. 4 and 26 and 33
35. randomized controlled trial.pt.
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44. exp animals/ not humans.sh.
45. 43 not 44
46. 34 and 45
Lines 35 to 45 are the Cochrane highly sensitive search strategy
for identifying randomized trials in MEDLINE (Ovid version)
(Lefebvre 2008)
Searching other resources
We will screen the reference lists of identified RCTs and review
articles to identify additional publications. We will identify addi-
tional ongoing trials by searching Google Scholar.
Unpublished trials
We will request information on unpublished trials from authors
of published studies and experts and information groups in the
areas of ADHD and amphetamines.
Data collection and analysis
Selection of studies
Two review authors (SP and LS) will independently screen all the
titles and abstracts retrieved from the search to identify those that
appear to meet the inclusion criteria. We will classify the abstracts
as either:
1. relevant (meeting all the prespecified inclusion criteria);
2. possible (meeting some, but not all, inclusion criteria); or
3. rejected (not relevant to the review, failing to meet any of
the inclusion criteria).
Both review authors will then assess the full journal articles of all
studies classified in categories 1 and 2 according to an inclusion/
exclusion checklist.Wewill contact study authors up to three times
if necessary to obtain information about unpublished studies or to
obtain additional information to resolve questions about relevance
of trials. We will resolve any disagreements by discussion, but
where this is not possible, SV will adjudicate.
Data extraction and management
Two review authors (SP and LS) will independently extract data
related to studymethods, participant characteristics, and outcomes
by using a predesigned data collection form. We will resolve any
disagreements by discussion, and if need be, SV will adjudicate.
SP will enter all relevant data into Review Manager 5.1 (RevMan
2011) and LS will double-check this.
Assessment of risk of bias in included studies
For each included study, two review authors (SP and LS) will
independently assess the risk of bias in the sevendomains explained
below using the Cochrane ’Risk of bias’ tool (Higgins 2011). We
will resolve disagreements by discussion, but where this is not
possible, SV will adjudicate.
We will assess the following sources of bias as being at low risk of
bias, high risk of bias, or unclear (uncertain) risk of bias.
Random sequence generation
We will examine the method used to generate the allocation se-
quence in sufficient detail to allow an assessment of whether it
should produce comparable groups. Review authors’ judgement:
what is the risk of selection bias due to inadequate generation of
a randomized sequence?
Allocation concealment
We will examine the method used to conceal the allocation se-
quence in sufficient detail to determine whether intervention allo-
cations could have been foreseen in advance of, or during, enrol-
ment. Review authors’ judgement: what is the risk of selection bias
due to inadequate concealment of allocations prior to assignment?
Blinding of participants and personnel
We will examine measures used, if any, to blind study participants
and personnel fromknowledge of which intervention a participant
received and any information relating to whether the intended
blinding was effective. Review authors’ judgement: what is the risk
of performance bias due to knowledge of the allocated interven-
tions by participants and personnel during the study?
Blinding of outcome assessment
We will examine measures used, if any, to blind outcome assessors
from knowledge of which intervention a participant received and
any information relating to whether the intended blinding was
effective. Review authors’ judgement: what is the risk of detection
bias due to knowledge of the allocated interventions by outcome
assessors?
Incomplete outcome data
We will examine data on attrition and exclusions and report the
numbers involved (compared with total), reasons for attrition/ex-
clusion where reported, or obtained from investigators, and any
re-inclusions in analyses performed by review authors. Review au-
thors’ judgement: what is the risk of attrition bias due to amount,
nature, or handling of incomplete outcome data?
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Selective reporting
We will examine attempts to assess the possibility of selective
outcome reporting by investigators. We will attempt to retrieve
the original protocols for each included study and compare the
planned outcomes with the outcomes reported. Review authors’
judgement: what is the risk of reporting bias due to selective out-
come reporting?
Other sources of bias
We will make attempts to address sources of bias in other domains
not covered by the tool. These include source of funding, conflicts
of interest, and validity of outcome measures. Review authors’
judgement: what is the risk of bias due to problems not covered
elsewhere in the table?
Measures of treatment effect
Dichotomous outcome data
We plan to report risk ratio (RR) and 95% confidence intervals
(CIs) for dichotomous outcomes.
Continuous outcome data
For continuous outcomes, where the same rating scale has been
used for all studies, we will calculate mean differences (MDs) and
95% CI; where different rating scales are used, we will calculate
standardized mean differences (SMDs). Hedges’ method will be
used for calculating SMDwith individual study weights calculated
as the inverse of the variance. To ensure all scales are pointing in
the same direction, we will multiply the mean values of one set
by -1 (Higgins 2011). For the primary outcome, we will combine
change scores and endpoint scores; however, we will give priority
to change scores when both types of scores are available in the
same study.
Unit of analysis issues
Cross-over trials
Our analysis will include both parallel and cross-over trials that will
be combined in the same meta-analysis. For outcomes that use a
MD, we will compute standard deviations (SDs) for the cross-over
studies taking into account correlation. If correlation coefficients
are not available, we will impute them from other studies or use
0.5 as a conservative estimate (Follman 1992). For outcomes using
SMD, we will treat cross-over studies as if they were parallel and
compute a pooled SD that does not take into account the cross-
over. This will prevent overestimation of effect size.
In situations where carry-over is thought to be a problem, where
no washout period is present, or when only data from the first
period are available, we will analyze data from the first period only.
Studies with multiple comparisons
When more than two independent comparisons are available, for
example, amphetamine versus placebo versus psychotherapy, we
will not include the psychotherapy arm. In studies with multi-
ple and correlated interventions, for example, lisdexamphetamine
versus mixed amphetamine salts versus placebo, or 10 mg of am-
phetamine versus 20 mg of amphetamine versus placebo, we will
combine the two experimental groups using the formulae de-
scribed in Table 7.7.a of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). Because we have planned a
subgroup analysis for the different formulations of amphetamines,
in order to avoid double-counts in the shared intervention groups
(in this case placebo) for dichotomous outcomes, wewill divide up
both the number of events and number of participants. For con-
tinuous outcomes, we will divide up the total number of partici-
pants, while the means and SDs will be left unchanged (Higgins
2011).
Studies with multiple measures
When a single study provides multiple measures of the same out-
come at the same point in time (for example, two measures used
to assess ADHD severity), we will average the effects across the
outcomes to arrive at a single effect for use in the meta-analysis.
Studies with multiple time points
In studies where results are presented for several periods of fol-
low-up, we will analyze each outcome at each point in a separate
meta-analysis with other comparable studies taking measures at a
similar time frame post-randomization. Time frames will reflect
short-term (up to six months), medium-term (between six and 12
months), and long-term (over 12 months) outcomes.
Dealing with missing data
We will contact authors of included studies up to three times to
obtain missing data. If studies have not reported outcomes using
intention-to-treat analysis, and the missing data are unattainable,
we will perform an available case analysis for both dichotomous
and continuous outcomes. If studies have not reported the SD, it
will be calculated from P values, t values, CIs, or standard errors
(as described in section 7.7.3.3 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011)). If this informa-
tion is not reported or unattainable, the SD from the study with
the highest SD for that outcome will be imputed. To assess the
effect of missing data on the analysis, we will conduct a sensitivity
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analysis for that outcome by showing our results with our imputed
SD versus a lower imputed SD.
Assessment of heterogeneity
We will investigate clinical heterogeneity by performing subgroup
analyses according to important clinical characteristics (presence
of comorbid conditions; ADHD subtype), pharmacological char-
acteristics (form of amphetamine used), study funding (pharma-
ceutically funded or not), and study design (cross-over versus par-
allel). We will explore statistical heterogeneity by examining the I
2 index (Higgins 2011), which is used to quantify the degree of
heterogeneity in a meta-analysis. An I2 > 50% in the primary anal-
ysis is indicative of statistical heterogeneity and we will determine
whether to further explore clinical heterogeneity by performing
subgroup analysis. We will calculate a pooled effect size for each
subgroup.
Assessment of reporting biases
If we have identified a sufficient number of studies (n ≥ 10) for
inclusion,wewill draw funnel plots in order to assess the possibility
of publication bias. The degree of asymmetry will be examined
using the Egger test (Egger 1997). Such a relationship could be
due to publication bias, the relationship between trial size and
effect size, or chance. If unpublished studies are included in the
review, we will conduct a sensitivity analysis of published versus
unpublished studies.
Data synthesis
Where we consider studies to be sufficiently homogenous in terms
of participants (age, gender, etc), interventions (dosage, frequency,
etc), and outcomes, we plan to synthesize results in a meta-analysis
using the random-effects model. We will perform statistical analy-
sis using The Cochrane Collaboration’s Review Manager Software
(RevMan 2011).
Subgroup analysis and investigation of heterogeneity
If data permit, we will conduct subgroup analyses classifying the
trials as follows.
1. Comorbidities: presence of comorbid ODD/CD or not.
2. Type of amphetamine: amphetamine, dextroamphetamine,
lisdexamphetamine, or mixed amphetamine salts.
3. Type of drug release formulation: long-acting or immediate
release.
4. Type of questionnaire used: completed by teacher, parent,
clinician, investigator, or self.
5. Type of ADHD subtype: inattentive type, hyperactive-
impulsive type, or combined type.
Sensitivity analysis
We will conduct sensitivity analyses classifying trials according to
the following criteria.
1. Risk of bias assessment: each outcome meta-analysis will be
restricted to those studies with a low risk of bias. A study is
defined as having a low risk of bias if all domains of the risk of
bias tool score a low risk of bias.
2. Study design: cross-over versus parallel RCTs.
3. Studies reporting the primary outcome as a change from
baseline versus endpoint value.
4. Fixed-effect model of meta-analysis versus random-effects
model.
5. Unpublished versus published studies.
6. Imputed SD versus lower imputed SD (in the event of
missing data).
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SP will lead the design and ongoing co-ordination of this review with oversight from LS, LH, LU, BV, CJN, and SV.
SP developed the additional search strategies and will carry out the searches for this review.
SP and BV developed the analysis plan.
SP will retrieve the papers for this review.
SP and LS will screen the retrieved papers against the inclusion criteria for this review.
SP and LS will independently appraise the risk of bias in the papers for this review.
SP and LS will independently extract the data from the papers for this review.
SP will write to authors of included studies for additional information for this review.
SP will manage the data for this review including entering data into RevMan and analyzing the data under the guidance of BV.
SP will interpret the data for this review with input from all authors.
SP will write the review.
All authors will critically read and edit the review prior to submission.
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